Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-06-17
2003-06-17
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266400, C514S303000, C514S365000, C514S378000
Reexamination Certificate
active
06579894
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the field of transfer ribonucleic acid (tRNA) synthetase inhibitors, their preparation and their use as antimicrobial agents.
BACKGROUND OF THE INVENTION
Aminoacyl tRNA synthetases (aaRS) are a family of essential enzymes that are found in virtually every biological cell and are responsible for maintaining the fidelity of protein synthesis. They specifically catalyze the aminoacylation of tRNA in a two step reaction:
amino acid (AA)+ATP=>AA-AMP+PPi AA-AMP+tRNA=>tRNA-AA+AMP
The enzyme binds adenosine triphosphate (ATP) and its specific amino acid to catalyze formation of an aminoacyl adenylate complex (AA-AMP) with concomitant release of pyrophosphate (PPi). In the second step, the amino acid is transferred to the 2′ or 3′ terminus of the tRNA yielding “charged” tRNA and adenosine monophosphate (AMP). The charged tRNA delivers the amino acid to the nascent polypeptide chain on the ribosome.
There are at least twenty essential enzymes in this family for each organism. Inhibition of any of the essential tRNA synthetases disrupts protein translation, ultimately resulting in growth inhibition. Pseudomonic acid A, an antibacterial agent currently used in human therapy, provides clear evidence of the utility of tRNA synthetase inhibitors as useful pharmaceuticals. Pseudomonic acid A binds to one particular tRNA synthetase, isoleucyl tRNA synthetase, and inhibits isoleucyl adenylate formation in several Gram positive bacterial pathogens such as
Staphylococcus aureus
, resulting in the inhibition of protein synthesis, followed by growth inhibition. Novel synthetic compounds that target tRNA synthetases offer clear advantages as useful therapeutic agents to curb the threat of drug resistance. Drug resistance allows a pathogen to circumvent the biochemical disruption caused by an antimicrobial agent. This resistance can be a result of a mutation that has been selected for and maintained. Pathogens in the environment have had repeated exposure to current therapeutics. This exposure has led to the selection of variant antimicrobial strains resistant to these drugs.
Novel synthetic antimicrobial agents, therefore, would be expected to be useful to treat drug resistant pathogens, since the pathogen has never been exposed to the novel antimicrobial agent. The development of compounds or combinations of compounds targeting more than one tRNA synthetase is also advantageous. Accordingly, inhibition of more than one enzyme should reduce the incidence of resistance since multiple mutations in a pathogen would be required and are statistically rare.
SUMMARY OF THE INVENTION
The present invention discloses novel compounds which inhibit tRNA synthetases and have efficacy, including whole cell killing, against a broad spectrum of bacteria and fungi. Described herein are compounds that exhibit tRNA synthetase inhibition.
The present invention comprises, in one aspect, compounds of Formula I.
Group Ar of Formula I is selected from aryl or heteroaryl. Preferably, Ar is aryl, more preferably, substituted phenyl, even more preferably, 2,4-dichlorophenyl.
Group L of Formula I is selected from —C(O)N(Q)CH
2
—, or —CR
10
R
11
OCR
12
R
13
—; wherein Q is selected from hydrido, —(CH
2
)
m
CO
2
H or —(CH
2
)
m
CO
2
CH
3
; and wherein m is a whole number from 1-4. Preferably, L is —C(O)NHCH
2
—.
Each of substituents R
1
, R
2
, R
9
, R
10
, R
11
, R
12
, and R
13
of Formula I is independently selected from hydrido or lower alkyl, preferably hydrido.
Each of substituents R
3
, R
4
, R
5
, R
6
, R
7
, and R
8
of Formula I is independently selected from hydrido, acyl, amino, cyano, acyloxy, acylamino, carboalkoxy, carboxyamido, carboxy, halo, thio, alkyl, heteroaryl, heterocyclyl, alkoxy, aryloxy, sulfoxy, N-sulfonylcarboxyamido, N-acylamino sulfonyl, hydroxy, aryl, cycloalkyl, sulfinyl, or sulfonyl. Additionally, R
3
and R
4
together or R
5
and R
6
together or R
7
and R
8
together are selected from
wherein each of R
14
, R
15
and R
16
is independently selected from hydrido, alkyl or carboxy-substituted alkyl; provided that at least five of R
3
, R
4
, R
5
, R
6
, R
7
, and R
8
are independently hydrido. Preferably, each of R
3
, R
4
, R
5
, R
6
, R
7
, and R
8
is independently selected from hydrido, hydroxy, alkoxy, alkyl, amino, and carboxyamido. More preferably, each of R
3
, R
4
, R
5
, R
6
, R
7
, and R
8
is independently selected from hydrido, —O(CH
2
)
n
CO
2
R
17
, —O(CH
2
)
n
CONHSO
2
R
18
, —(CH
2
)
n
CO
2
R
19
, —(CH
2
)
n
CONHSO
2
R
20
, —C(O)NHCH(R
22
)CO
2
R
21
, or —N(R
23
)(CH
2
)
n
CO
2
R
24
, wherein each of R
17
, R
19
, R
21
, R
22
, R
23
, and R
24
is independently selected from hydrido or alkyl; wherein each of R
18
and R
20
is independently alkyl; wherein n is selected from 1 or 2. Even more preferably, each of R
3
, R
4
, R
6
, R
7
, and R
8
is hydrido and R
5
is selected from —O(CH
2
)
n
CO
2
R
17
, —O(CH
2
)
n
CONHSO
2
R
18
, —(CH
2
)
n
CO
2
R
19
, —(CH
2
)
n
CONHSO
2
R
20
, C(O)NHCH(R
22
)—CO
2
R
21
, or —N(R
23
)(CH
2
)
n
CO
2
R
24
.
Group Het of Formula I is selected from
wherein X is selected from N or CR
27
; wherein Y is selected from NH, S or O; wherein Z is selected from N or CR
28
; wherein each of R
25
, R
26
, R
27
, and R
28
is independently selected from nitro, halo, hydroxy, lower amino, lower alkyl, lower alkoxy, aryloxy, lower carboalkoxy, sulfinyl, sulfonyl, carboxy, lower thio, and sulfoxy; and wherein each of R
29
, R
30
, and R
31
is selected from hydrido, alkyl, aryl, nitro, amino, sulfonyl or sulfinyl. Preferably, Het is
The invention also embraces pharmaceutically-acceptable salts of the forgoing compounds.
A further aspect of the invention comprises using a composition comprising the compound(s) of Formula I to inhibit a tRNA synthetase and in particular, to modulate the growth of bacterial or fungal organisms in mammals, a plant or a cell culture.
Yet another aspect of the invention involves a method of inhibiting the growth of microorganisms. The method involves exposing the microorganism to a compound of the invention, preferably a compound of Formula I, under conditions whereby a therapeutically effective amount of the compound enters the microorganism. The method is useful for inhibiting the growth of microrganisms in vivo and in vitro.
Another aspect of the invention is a pharmaceutical composition comprising the compound(s) of the invention and, in particular, the compounds of Formula I, useful in the treatment of microbial infections, e.g., bacterial infections, fungal infections. A related aspect of the invention is a method of making a medicament which involves placing a compound(s) of the invention, preferably a compound of Formula I, in a suitable pharmaceutically acceptable carrier.
These and other aspects of the invention will be more apparent in reference to the following detailed description of the invention.
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
Molecular terms, when used in this application, have their common meaning unless otherwise specified. The term “hydrido” denotes a single hydrogen atom (H). The term “acyl” is defined as a carbonyl radical attached to a hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycyl, aryl or heteroaryl group, examples of such radicals being formyl, acetyl and benzoyl. The term “amino” denotes a nitrogen radical containing two substituents independently selected from the group consisting of hydrido, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl. Preferred amino radicals are NH
2
radicals and “lower amino” radicals, whereby the two substituents are independently selected from hydrido and lower alkyl. A subset of amino is “alkylamino”, whereby the nitrogen radical contains at least 1 alkyl substituent. Preferred alkylamino groups contain alkyl groups that are substituted, for example, with a carboalkoxy group. The term “acyloxy” denotes an oxygen radical adjacent to an acyl group. The term “acylamino” denotes a nitrogen radical adjacent to an acyl, carboalkoxy or carbo
Finn John
Hammond Milton L.
Keith Dennis
Leeman Aaron H.
Maletic Milana
Daniel Mark R.
Hunter, Jr. James M.
Merck & Co. , Inc.
LandOfFree
Prolines as antimicrobial agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prolines as antimicrobial agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prolines as antimicrobial agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3091484